Navigation Links
Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Date:5/22/2012

first-in-class, selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor being investigated for its potential in treating patients with chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, and multiple myeloma, all of which are considered B-cell malignancies.  Ibrutinib is being jointly developed by Pharmacyclics, Inc. and Janssen Biotech, Inc.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
3. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
6. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
7. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
8. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
10. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
11. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... in Consumer Healthcare by Application, Sensor Type & by ... 2020" report to their offering. ... an increasing momentum for consumer healthcare monitoring and sensing ... consumer healthcare will lessen the healthcare cost of the ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, ... in translational preclinical research, today unveiled their new logo ... the transformation of Surpass, corporate culture to one where ... customers. This press release comes on the heels of ... added to the Silicon Valley Team:  David Craig, a ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
(Date:7/23/2014)... Vancouver, BC (PRWEB) July 23, 2014 ... has recently announced the launch of its custom orthotics ... correcting and eliminating foot abnormalities in order to restore ... the joints and cause less fatigue and pain. In ... and reduced pressure in the foot, resulting in relief ...
(Date:7/23/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... a topic that is quickly becoming among the most important ... The Best Drug Rehabilitation blog post on opiate abuse facts ... why they’re considered “the mother of all Schedule II drugs” ...
(Date:7/23/2014)... Children and teens who lose a parent might face an ... study suggests. People who were children or teens when ... death during the study period than those who had not ... Although the study found an association between a parent,s ... wasn,t designed to prove cause-and-effect. Also, the increased risk ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The European ... in Europe with analysis and projection of revenue. The ... $812.03 million in 2012 to $1,202.08 million by 2018, ... , Browse through the TOC of the European Vitamins ... analysis provided. This also provides a glimpse of the ...
(Date:7/23/2014)... a distinguished electrical equipment retailer, has recently unveiled its collection ... company has decided to provide big price cuts for all ... for the company’s brand new SMA JACK can get a ... quality SMA JACK from RFcnn.com Provides a great help . ... to help make things much easier for worldwide distributors. It ...
Breaking Medicine News(10 mins):Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:New Collection of SMA JACK Released by China Electrical Accessory Manufacturer RFcnn 2
... has developed new guidelines for starting and monitoring treatments ... first JIA guidelines endorsed by the ACR, with the ... Created as a guide for health care providers, ... of multiple medications used in the treatment of JIA, ...
... venues and a lack of motivation even if those ... for adolescent boys, according to recently published research from a ... boys, attitudes led by Lorraine Robbins from MSU,s College of ... the decrease in exercise typically seen in this age group. ...
... , WEDNESDAY, March 30 (HealthDay News) -- Longer periods ... larger brain growth in offspring, which explains why human ... say researchers. They also said the findings from ... offer further proof that breast-feeding is good for brain ...
... at diagnosis for chronic myeloid leukemia (CML) is over 60 ... data are available about the long-term outcome for older patients ... CML. Results from a study published today in ... of Hematology , reveal that age does not affect response ...
... reduced the blood pressure of a 76-year-old woman ... total knee replacement surgery for osteoarthritis (OA). While ... the woman,s blood pressure dropped dramatically when she ... the April issue of Arthritis Care & ...
... HealthDay Reporter , TUESDAY, March 29 (HealthDay News) -- While ... New research suggests that some people with the disease apparently ... kidney and heart disease. In a group of ... years, nearly 43 percent remained free of serious eye disease, ...
Cached Medicine News:Health News:New clinical practice guidelines developed for juvenile idiopathic arthritis 2Health News:New clinical practice guidelines developed for juvenile idiopathic arthritis 3Health News:Lack of motivation, equipment main barriers for exercise for boys 2Health News:Longer Breast-Feeding May Be Key to Bigger Brains 2Health News:Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib 2Health News:Case study reports singing lowers patient's blood pressure prior to surgery 2Health News: Some Type 1 Diabetics Seem Shielded Against Complications 2Health News: Some Type 1 Diabetics Seem Shielded Against Complications 3Health News: Some Type 1 Diabetics Seem Shielded Against Complications 4
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
Medicine Products: